These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39140065)

  • 1. Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Aug; 15(8):1184-1185. PubMed ID: 39140065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.
    Sabnis RW
    ACS Med Chem Lett; 2024 Aug; 15(8):1203-1204. PubMed ID: 39140054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fused Bicyclic Heteroaryl Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):895-896. PubMed ID: 37465294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1,2,4-Triazine Derivatives as NLRP3 Inhibitors for Treating Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2023 May; 14(5):547-548. PubMed ID: 37197471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson's Disease, and Alzheimer's Disease.
    Sabnis RW
    ACS Med Chem Lett; 2023 Aug; 14(8):1047-1048. PubMed ID: 37583813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Apr; 15(4):443-444. PubMed ID: 38628783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitrogen-Containing 2,3-Dihydroquinazolinone Compounds as Na
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):893-894. PubMed ID: 37465303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Myeloperoxidase Inhibitors for Treating Multiple Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 May; 15(5):569-570. PubMed ID: 38746891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jul; 15(7):994-995. PubMed ID: 39015277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Feb; 15(2):177-178. PubMed ID: 38352847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel HSD17B13 Inhibitors for Treating Liver Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):771-772. PubMed ID: 38894932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Heterocyclic PAD4 Inhibitors for Treating Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Mar; 15(3):340-341. PubMed ID: 38505857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Feb; 15(2):179-180. PubMed ID: 38352837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boron-Containing Pyrazole Compounds as JAK Inhibitors for Treating Inflammation, Autoimmune Diseases, and Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2022 Oct; 13(10):1554-1555. PubMed ID: 36267133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Compounds as TEAD Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Sep; 14(9):1152-1153. PubMed ID: 37736181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):769-770. PubMed ID: 38894908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel IRAK4 Inhibitors for Treating Asthma, COPD, Cancer, Autoinflammatory Diseases, and Autoimmune Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2023 Dec; 14(12):1617-1618. PubMed ID: 38116447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):775-776. PubMed ID: 38894910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):748-749. PubMed ID: 38894901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma.
    Sabnis RW
    ACS Med Chem Lett; 2023 Oct; 14(10):1336-1337. PubMed ID: 37849559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.